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high CRP level (tertile 3). Results: Plasma fetuin-A and CRP concentrations at
admission averaged 95±27mg/L and 11±16UI, respectively with low fetuin-A
defined as <69mg/L and high CRP level as 25UI. At one year follow up
(n=726, 97%), cardiovascular mortality (n=50, 7%) was 16% (18/111), 9%
(21/250) and 3% (11/365) in patients with low fetuin-A/high CRP (n=111),
either low fetuin or high CRP (n=250) and high fetuin-A/low CRP (n=365),
respectively. By multivaritate analysis low fetuin-A/high CRP level remained
independently predictive of outcome (OR=3.4 [1.6-7.3], p=0.001, Figure 1)
after adjustment to ST elevation, GRACE score and medical treatment. In con-
trast, CRP and fetuin-A alone failed to predict outcome. 
 
Conclusions:
 
 Inflammatory imbalance assessed by combining fetuin-A and
CRP values is an important predictor of cardiovascular death in ACS patients.
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Background:
 
 the impact of antidiabetic medications on clinical outcomes
in patients developing acute myocardial infarction (MI) is controversial. We
sought to determine whether in-hospital outcomes in patients who were on sul-
fonylureas (SUs) when they developed their MIs differed from those of dia-
betic patients not receiving SUs, and whether clinical outcomes were related
to the pancreatic cell specificity of SUs. 
 
Methods and Results:
 
 we analyzed the outcomes of the 1310 diabetic patients
included in the nationwide French registry of Acute ST-elevation and non ST-ele-
vation myocardial infarction (FAST-MI) in 2005. Medications used before the
acute episode were recorded. In-hospital complications were analyzed according to
prior antidiabetic treatment. Mortality was lower in patients previously treated with
SUs (3.9%), versus those on other oral medications (6.4%), insulin (9.4%) or no
medication (8.4%) (p=0.014). Among SU-treated patients, in-hospital mortality
was lower in patients receiving pancreatic cell-specific SUs (gliclazide or glime-
piride)(2.7%), compared with those on glibenclamide (7.5%) (p=0.019). Arrhyth-
mias and ischemic complications were also less frequent in patients receiving
gliclazide/glimepiride. The lower risk in patients receiving gliclazide/glimepiride
versus glibenclamide persisted after multivariate adjustment (OR=0.15; 95%CI:
0.04-0.56) and in propensity score-matched cohorts. 
 
Conclusion:
 
 In this nationwide registry of patients hospitalized for acute
MI, no hazard was associated with the use of SUs before the acute episode. In
addition, patients who had previously received gliclazide/glimepiride had
better in-hospital outcomes, compared to those on glibenclamide. 
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Background:
 
 In patients with acute myocardial infarction (MI), beta-bloc-
kers are recommended and contribute to control the heart rate (HR). The fac-
tors associated with HR and outcome of patients discharged with HR>70 beats
per minute (bpm) is poorly documented.
 
Methods:
 
 Prospective registry including patients with acute MI. Recorded
variables corresponded to the CARDS dataset. The proportion of patients dis-
charged with HR>70 bpm was assessed. Multivariate regression was used to deter-
mine factors associated with HR at discharge and logistic regression was used to
determine the prognostic value of high HR at discharge on 30 day mortality. 
 
Results:
 
 Among the 837 patients, 592 survived and were discharged with
a beta blocker. Discharge HR was 
 
≤
 
 70 bpm in 61% when a betablocker was
given and in 31% without beta blocker (p<0.001). Discharge HR was asso-
ciated with older age, admission HR, admission systolic blood pressure, BNP
level, diabetes, use of beta blockers and ACEI. Patients discharged with
HR>70 bpm (n=227, 39%) had a threefold higher mortality as compared with
those with HR
 
≤
 
 70 (figure). Multivariate analysis showed that a HR
 
≥
 
70 at dis-
charge was an independent predictor of 30 day mortality on top of the GRACE
risk score and use of beta blockers.
 
Conclusions:
 
 Among patients discharged after acute MI, those with
HR>70 have higher 30 day mortality, independently of the GRACE risk score
and use of beta blockers.
Mortality by discharge heart rate
